Brief: Durable And Deepening Clinical Responses Observed In Post-Treatment Period Of Evelo Bioscience’S Phase 2 Clinical Trial Of Oral Edp1815 In Psoriasis

Evelo Biosciences

28/02/2022 11:08

Feb 28 (Reuters) - Evelo Biosciences Inc  EVLO.O :
    * DURABLE AND DEEPENING CLINICAL RESPONSES OBSERVED IN
POST-TREATMENT PERIOD OF EVELO BIOSCIENCE’S PHASE 2 CLINICAL
TRIAL OF ORAL EDP1815 IN PSORIASIS
    * EVELO BIOSCIENCES INC - 18/30 PATIENTS MAINTAINED A
PASI-50 OR
GREATER RESPONSE AT 24 WEEKS POST-TREATMENT
    * EVELO BIOSCIENCES INC - 9/20 PATIENTS EXPERIENCED A
DEEPENING OF
RESPONSE FROM PASI-50 TO AT LEAST PASI-75 DURING POST-TREATMENT
PERIOD
    * EVELO BIOSCIENCES INC - NO FLARE OR REBOUND OBSERVED
FOLLOWING
DISCONTINUATION OF TREATMENT
    * EVELO BIOSCIENCES INC - TOLERABILITY AND SAFETY DATA FOR
EDP1815
IN TRIAL WAS COMPARABLE TO PLACEBO

Source text for Eikon:  ID:nGNX1qRsSp 
Further company coverage:  EVLO.O 

 ((Reuters.Briefs@thomsonreuters.com;))